The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas
Summary: Diffuse glioma is the most prevalent and malignant brain tumor. The function and significance of CD37 in diffuse gliomas remain largely unknown. Here, we showed CD37 was abnormally expressed in diverse cancers, especially glioma by pan-cancer differential expression analysis. In addition, w...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5dabd7a74ec54a09899c4443834b2b51 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:5dabd7a74ec54a09899c4443834b2b51 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:5dabd7a74ec54a09899c4443834b2b512021-11-20T05:08:51ZThe clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas2589-004210.1016/j.isci.2021.103249https://doaj.org/article/5dabd7a74ec54a09899c4443834b2b512021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2589004221012189https://doaj.org/toc/2589-0042Summary: Diffuse glioma is the most prevalent and malignant brain tumor. The function and significance of CD37 in diffuse gliomas remain largely unknown. Here, we showed CD37 was abnormally expressed in diverse cancers, especially glioma by pan-cancer differential expression analysis. In addition, we found CD37 was upregulated in higher grade and IDH or IDH1-wildtype gliomas, which was further validated by qPCR and IHC. Survival analysis revealed CD37 served as an independent indicator for unfavorable prognosis of patients with diffuse gliomas. Functional enrichment analysis revealed CD37 was associated with immunological processes. Moreover, immune infiltration analyses suggested gliomas with high-expression CD37 had greater infiltration of M2 macrophages and neutrophils, and lower NK cell abundance. CD37 was closely correlated to immune checkpoint molecules, including CD276, CD80, CD86, and PD-L2. Our results indicated CD37 is an independent prognostic factor and plays an immunosuppressive role in diffuse gliomas. Targeting CD37 could be a promising immunotherapeutic strategy for diffuse gliomas.Xuejun YanQuanwei ZhouHecheng ZhuWeidong LiuHongjuan XuWen YinMing ZhaoXingjun JiangCaiping RenElsevierarticleImmunologyCancerScienceQENiScience, Vol 24, Iss 11, Pp 103249- (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Immunology Cancer Science Q |
| spellingShingle |
Immunology Cancer Science Q Xuejun Yan Quanwei Zhou Hecheng Zhu Weidong Liu Hongjuan Xu Wen Yin Ming Zhao Xingjun Jiang Caiping Ren The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas |
| description |
Summary: Diffuse glioma is the most prevalent and malignant brain tumor. The function and significance of CD37 in diffuse gliomas remain largely unknown. Here, we showed CD37 was abnormally expressed in diverse cancers, especially glioma by pan-cancer differential expression analysis. In addition, we found CD37 was upregulated in higher grade and IDH or IDH1-wildtype gliomas, which was further validated by qPCR and IHC. Survival analysis revealed CD37 served as an independent indicator for unfavorable prognosis of patients with diffuse gliomas. Functional enrichment analysis revealed CD37 was associated with immunological processes. Moreover, immune infiltration analyses suggested gliomas with high-expression CD37 had greater infiltration of M2 macrophages and neutrophils, and lower NK cell abundance. CD37 was closely correlated to immune checkpoint molecules, including CD276, CD80, CD86, and PD-L2. Our results indicated CD37 is an independent prognostic factor and plays an immunosuppressive role in diffuse gliomas. Targeting CD37 could be a promising immunotherapeutic strategy for diffuse gliomas. |
| format |
article |
| author |
Xuejun Yan Quanwei Zhou Hecheng Zhu Weidong Liu Hongjuan Xu Wen Yin Ming Zhao Xingjun Jiang Caiping Ren |
| author_facet |
Xuejun Yan Quanwei Zhou Hecheng Zhu Weidong Liu Hongjuan Xu Wen Yin Ming Zhao Xingjun Jiang Caiping Ren |
| author_sort |
Xuejun Yan |
| title |
The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas |
| title_short |
The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas |
| title_full |
The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas |
| title_fullStr |
The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas |
| title_full_unstemmed |
The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas |
| title_sort |
clinical features, prognostic significance, and immune heterogeneity of cd37 in diffuse gliomas |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/5dabd7a74ec54a09899c4443834b2b51 |
| work_keys_str_mv |
AT xuejunyan theclinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT quanweizhou theclinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT hechengzhu theclinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT weidongliu theclinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT hongjuanxu theclinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT wenyin theclinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT mingzhao theclinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT xingjunjiang theclinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT caipingren theclinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT xuejunyan clinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT quanweizhou clinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT hechengzhu clinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT weidongliu clinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT hongjuanxu clinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT wenyin clinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT mingzhao clinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT xingjunjiang clinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas AT caipingren clinicalfeaturesprognosticsignificanceandimmuneheterogeneityofcd37indiffusegliomas |
| _version_ |
1718419543239426048 |